| scholarly article | Q13442814 |
| P50 | author | Gian Domenico Sebastiani | Q77434471 |
| Haner Direskeneli | Q88366048 | ||
| Roberto Cattaneo | Q88591752 | ||
| Daniel Blockmans | Q88953452 | ||
| Frederic A Houssiau | Q90710486 | ||
| Ahmet Gul | Q92474749 | ||
| Alessandro Mathieu | Q114314184 | ||
| Enrique de Ramon Garrido Ed | Q114416244 | ||
| Daniel Abramovicz | Q114416245 | ||
| Rajko Popovic | Q114416246 | ||
| Renato Alberto Sinico | Q114416247 | ||
| Geneviève Depresseux | Q114416248 | ||
| Jean-Pierre Cosyns | Q114416249 | ||
| Ricard Cervera i Segura | Q53547424 | ||
| Carlos Vasconcelos | Q56750258 | ||
| Maria Giovanna Danieli | Q58128912 | ||
| Yair Levy | Q73255332 | ||
| Josep Font | Q73474655 | ||
| Mauro Galeazzi | Q73480279 | ||
| P2093 | author name string | David D'Cruz | |
| Peter Petera | |||
| Radmila Petrovic | |||
| P2860 | cites work | The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 |
| Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis | Q33564864 | ||
| Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis | Q34244145 | ||
| Mycophenolate mofetil: a review of its use in the management of solid organ transplantation | Q37010130 | ||
| Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study | Q37153391 | ||
| Treatment of lupus nephritis: a meta-analysis of clinical trials | Q40906582 | ||
| Treatment of lupus nephritis--the advantages of a flexible approach | Q41627127 | ||
| Minimisation: the platinum standard for trials?. Randomisation doesn't guarantee similarity of groups; minimisation does | Q42757892 | ||
| Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. | Q43711419 | ||
| A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. | Q46186465 | ||
| P433 | issue | 8 | |
| P921 | main subject | lupus nephritis | Q1621830 |
| P304 | page(s) | 2121-2131 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide | |
| P478 | volume | 46 |
| Q38833868 | A critical review of clinical trials in systemic lupus erythematosus |
| Q42511206 | A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full? |
| Q37577571 | A perspective on B-cell-targeting therapy for SLE. |
| Q27026880 | A treatment algorithm for children with lupus nephritis to prevent developing renal failure |
| Q38460505 | Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions |
| Q38734009 | Abatacept for the treatment of systemic lupus erythematosus. |
| Q43930141 | Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome |
| Q38211917 | Acute respiratory failure during first cyclophosphamide infusion in a patient with systemic lupus erythematosus |
| Q36802101 | Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review |
| Q53096167 | After 4 Decades of Lupus Nephritis Trials, Is There a "Best" Therapy? |
| Q87568136 | Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy |
| Q36221407 | American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis |
| Q37378976 | An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases |
| Q38418254 | Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review |
| Q46903227 | Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria |
| Q39812231 | Anti-Sm is associated with the early poor outcome of lupus nephritis |
| Q35778456 | Aspergillus-associated cerebral aneurysm successfully treated by endovascular and surgical intervention with voriconazole in lupus nephritis patient |
| Q38366057 | Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years |
| Q33929673 | Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: a case-control study |
| Q34409787 | Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial |
| Q79839545 | Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial |
| Q33542751 | B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data |
| Q38026784 | B-cell depletion in the treatment of lupus nephritis |
| Q37960525 | Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus |
| Q54948758 | Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review. |
| Q34455827 | Belimumab for the treatment of systemic lupus erythematosus |
| Q33695128 | Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study |
| Q92513141 | Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review |
| Q38943485 | Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone |
| Q79977805 | Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis? |
| Q92550893 | Changing paradigms in the treatment of systemic lupus erythematosus |
| Q87393398 | Chapter 12: Lupus nephritis |
| Q98158778 | Chemoprotective effects of inositol hexaphosphate against cyclophosphamide-induced testicular damage in rats |
| Q38223293 | Childhood onset systemic lupus erythematosus: how is it different from adult SLE? |
| Q37892917 | Clearing the complexity: immune complexes and their treatment in lupus nephritis |
| Q36752458 | Clinical features, epidemiology, and short-term outcomes of proliferative lupus nephritis in Eastern India |
| Q92908751 | Clinico-pathological considerations in a 48-years-old female with acute kidney injury: is it lupus nephritis, ANCA-associated vasculitis or something else? |
| Q36266807 | Clinicopathological findings, treatment response and predictors of long-term outcome in a cohort of lupus nephritis patients managed according to the Euro-lupus regime: a retrospective analysis in Sri Lanka |
| Q90433428 | Comparative efficacy and safety of low-dose and high-dose cyclophosphamide as induction therapy for lupus nephritis: a network meta-analysis |
| Q35544692 | Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials |
| Q35430178 | Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials |
| Q57370995 | Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis |
| Q36338094 | Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV: A single-centre retrospective study. |
| Q90451505 | Complications of Immunosuppression in Glomerular Disease |
| Q53497916 | Con: Biomarkers in glomerular diseases: putting the cart before the wheel? |
| Q45353017 | Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil |
| Q80946862 | Conference report--lupus nephritis: diagnosis, therapy, and outcomes |
| Q41540102 | Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis |
| Q36278355 | Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus |
| Q45994929 | Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis. |
| Q28645743 | Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America |
| Q38855495 | Current and Emerging Therapies for Lupus Nephritis |
| Q26741266 | Current and emerging treatment options in the management of lupus |
| Q33882751 | Current status of lupus nephritis |
| Q37168027 | Current treatment of lupus nephritis |
| Q34095231 | Cyclophosphamide and lupus nephritis: when, how, for how long? |
| Q36054857 | Cyclophosphamide in lupus nephritis |
| Q64280996 | Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus |
| Q35838299 | Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? |
| Q35824515 | Cyclophosphamide: new approaches for systemic lupus erythematosus |
| Q41981158 | Cytomegalovirus enteritis mimicking Crohn's disease in a lupus nephritis patient: a case report |
| Q46810854 | Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis. |
| Q91803887 | Delayed lupus nephritis in the course of systemic lupus erythematosus is associated with a poorer treatment response: a multicentre, retrospective cohort study in Japan |
| Q38059445 | Diagnosis and treatment of lupus nephritis flares--an update. |
| Q35577284 | Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus |
| Q36462580 | Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? |
| Q45812853 | Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort |
| Q35051164 | ESRD from lupus nephritis in the United States, 1995-2010 |
| Q33805412 | Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis |
| Q35025425 | Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset |
| Q37795641 | Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options. |
| Q47129569 | Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? |
| Q45184210 | Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial |
| Q81412112 | Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis |
| Q44525390 | Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study |
| Q47707507 | Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan |
| Q38101015 | Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review |
| Q44623048 | Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study |
| Q51140299 | Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. |
| Q38466691 | Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study |
| Q36219954 | Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis |
| Q51173136 | Efficacy and toxicity of treatments for nephritis in a series of consecutive lupus patients. |
| Q34490782 | Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis |
| Q34118894 | Efficacy of two cyclophosphamide regimens for the treatment of lupus nephritis in Puerto Ricans: low vs. standard dose |
| Q47569278 | Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis |
| Q35761089 | Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus |
| Q36066014 | Emergence of targeted immune therapies for systemic lupus |
| Q37391863 | European consensus statement on the terminology used in the management of lupus glomerulonephritis |
| Q35008162 | Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy |
| Q44397077 | Extracorporeal immunoadsorption of antibodies against the VRT-101 laminin epitope in systemic lupus erythematosus: a feasibility evaluation study |
| Q82298546 | Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement |
| Q46091413 | Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide |
| Q38246219 | Fertility preservation in patients receiving cyclophosphamide therapy for renal disease |
| Q45047982 | First international meeting on mycophenolate mofetil: an advance in the treatment of lupus 27 April 2004, St Thomas' Hospital, London, UK. |
| Q40325057 | Glomerular Diseases and Renal Transplantation: Pathogenic Pathways and Evolution of Therapeutic Interventions |
| Q37762438 | Glomerular disease: why is there a dearth of high quality clinical trials? |
| Q37978291 | Glucocorticoid use and abuse in SLE. |
| Q36020897 | Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation |
| Q36896784 | High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus |
| Q35078183 | IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment |
| Q57689077 | Immunosuppressive treatment for proliferative lupus nephritis |
| Q35552600 | Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment |
| Q28752150 | In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice |
| Q37671987 | Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis |
| Q46602225 | Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children |
| Q33690722 | Infection in systemic lupus erythematosus, similarities, and differences with lupus flare |
| Q38149856 | Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies |
| Q54452633 | Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. |
| Q39228582 | Infertility - Prevention and Management |
| Q37462538 | Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study |
| Q57294303 | Inhibition of microRNA-182-5p contributes to attenuation of lupus nephritis via Foxo1 signaling |
| Q82880943 | Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome) |
| Q37464013 | Interferon (IFN)-λ is a potential mediator in lupus nephritis |
| Q38182646 | Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus |
| Q61453815 | Intravenous Cyclophosphamide Therapy for Anti-IFN-Gamma Autoantibody-Associated Infection |
| Q37298723 | Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis |
| Q34124711 | Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis |
| Q36302245 | Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis |
| Q34397379 | Kidney transplantation in patients with systemic lupus erythematosus. |
| Q36787315 | LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus |
| Q37058776 | Latest advances in connective tissue disorders |
| Q36681801 | Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis |
| Q46467090 | Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. |
| Q42004318 | Long-term outcome of patients with lupus nephritis: a single center experience |
| Q36165790 | Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: Safety and efficacy during a 3-year follow-up |
| Q40115721 | Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis. |
| Q64123823 | Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial |
| Q79298359 | Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Behçet's disease |
| Q47318191 | Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study |
| Q26740487 | Lupus Nephritis in Asia: Clinical Features and Management |
| Q26740483 | Lupus Nephritis: A Different Disease in European Patients? |
| Q35505690 | Lupus enteritis: an uncommon manifestation of systemic lupus erythematosus |
| Q95592748 | Lupus nephritis |
| Q36054851 | Lupus nephritis flares |
| Q40619112 | Lupus nephritis in Latin American patients: 10-year results from a single medical center in Argentina |
| Q37399315 | Lupus nephritis in children - 10 years' experience. |
| Q38446941 | Lupus nephritis management guidelines compared |
| Q87198730 | Lupus nephritis: MAINTAINing perspective in lupus nephritis trials |
| Q34578139 | Lupus nephritis: a 15-year multi-centre experience in the UK. |
| Q35867038 | Lupus nephritis: an overview of recent findings |
| Q38608138 | Lupus nephritis: an update |
| Q35553102 | Lupus nephritis: current issues |
| Q22000837 | Lupus nephritis: current update |
| Q36085856 | Lupus nephritis: induction therapy |
| Q26998390 | Lupus nephritis: the evolving role of novel therapeutics |
| Q46416350 | Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide |
| Q37800295 | Major lupus organ involvement: severe lupus nephritis |
| Q35640956 | Management of refractory systemic rheumatic diseases |
| Q92625510 | Management strategies and future directions for systemic lupus erythematosus in adults |
| Q53633828 | Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. |
| Q58590914 | Membranous nephropathy followed by anti-glomerular basement disease: A case report and review of clinical presentation and treatment |
| Q36360811 | Metabolism and transport of oxazaphosphorines and the clinical implications |
| Q38095864 | Minimising steroids in lupus nephritis--will B cell depletion pave the way? |
| Q46901557 | Modern therapy for systemic lupus erythematosus |
| Q37709460 | Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE). |
| Q47880803 | Mycophenolate as induction therapy in lupus nephritis with renal function impairment |
| Q34613945 | Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study |
| Q43061715 | Mycophenolate mofetil for lupus nephritis |
| Q46484881 | Mycophenolate mofetil in the treatment of lupus nephritis--7 years on. |
| Q37290624 | Mycophenolate mofetil in the treatment of lupus nephritis. |
| Q46313788 | Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis |
| Q34975939 | Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis |
| Q55166851 | Mycophenolate or Cyclophosphamide in Lupus Nephritis: Which One to Use in Indian Patients? |
| Q54260329 | Mycophenolate versus Cyclophosphamide for Lupus Nephritis. |
| Q36458168 | Mycophenylate mofetil: what role in the treatment of lupus? |
| Q35885259 | National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia |
| Q36680040 | National trends in pediatric systemic lupus erythematosus hospitalization in the United States: 2000-2009 |
| Q59924786 | Neuropsychiatric systemic lupus erythematosus |
| Q46788946 | New therapeutic concepts for vasculitis and collagenosis |
| Q24649115 | New therapeutic strategies for systemic sclerosis--a critical analysis of the literature |
| Q90412368 | New therapeutic strategies in systemic lupus erythematosus management |
| Q81609248 | New therapies for systemic lupus erythematosus |
| Q36915693 | New treatment strategies for proliferative lupus nephritis: keep children in mind! |
| Q47837398 | Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. |
| Q26796871 | Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus |
| Q55379285 | Nonimmediate allergic reactions induced by Mesna. |
| Q37754557 | Novel approaches to therapy for systemic lupus erythematosus: update 2005. |
| Q36054877 | Novel therapies in lupus nephritis |
| Q46467087 | On the road to the optimal treatment of lupus nephritis: are we there yet? |
| Q38425824 | Optimizing the use of existing therapies in lupus. |
| Q36577362 | Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? |
| Q37415711 | Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option |
| Q36157955 | Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study |
| Q64235419 | Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis |
| Q37105605 | Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility |
| Q35918369 | Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide |
| Q38876110 | Overview of pathophysiology and treatment of human lupus nephritis |
| Q38771936 | Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus |
| Q35226072 | Pigmented villonodular synovitis of the hip in systemic lupus erythematosus: a case report |
| Q40710206 | Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012. |
| Q92470523 | Post-transplant Lupus Nephritis Recurrence: A Case Report and Review of the Literature |
| Q38156069 | Pragmatic approaches to therapy for systemic lupus erythematosus |
| Q90177663 | Prediction of prognosis and renal outcome in lupus nephritis |
| Q50702177 | Predictive factors of clinical outcome in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy. |
| Q41622314 | Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort |
| Q41552872 | Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort |
| Q37350893 | Predictors of major infections in systemic lupus erythematosus |
| Q37100267 | Pregnancy and autoimmune connective tissue diseases |
| Q39758027 | Pro: Cyclophosphamide in lupus nephritis |
| Q41746643 | Prognosis and therapy of inflammatory rheumatic diseases : Impact of renal manifestations |
| Q53098900 | Prognosis of proliferative lupus nephritis subsets in the Louvain Lupus Nephritis inception Cohort. |
| Q36054839 | Prognostic factors in lupus nephritis |
| Q47140189 | Proliferative lupus nephritis in the absence of overt systemic lupus erythematosus: A historical study of 12 adult patients |
| Q35824537 | Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? |
| Q64044243 | Recent advances in the management of systemic lupus erythematosus |
| Q37953243 | Recent advances in the treatment of lupus nephritis |
| Q33924437 | Recent clinical trials in lupus nephritis |
| Q38175493 | Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. |
| Q57945954 | References |
| Q87929541 | Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis |
| Q84590029 | Renal cocktail: too hard for a diabetic |
| Q41317916 | Renal flare prediction and prognosis in lupus nephritis Hispanic patients |
| Q34654954 | Renal involvement in autoimmune connective tissue diseases |
| Q38833873 | Rethinking biologics in lupus nephritis |
| Q39069721 | Retrospective review of lupus nephritis in a New Zealand multi-ethnic cohort |
| Q37678723 | Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. |
| Q33727015 | Rheumatic autoimmune diseases in women and midlife health |
| Q53633371 | Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. |
| Q38235185 | Rituximab and lupus--a promising pair? |
| Q46385089 | Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report |
| Q42597354 | Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis |
| Q38021183 | Role of TWEAK in lupus nephritis: a bench-to-bedside review |
| Q34424633 | Role of early repeated renal biopsies in lupus nephritis |
| Q64235512 | Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis |
| Q87705292 | Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study |
| Q38014716 | Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? |
| Q44108515 | Statement on the use of mycophenolate mofetil for systemic lupus erythematosus |
| Q36729072 | Stronger Correlation between Interleukin 18 and Soluble Fas in Lupus Nephritis Compared with Mild Lupus |
| Q51152275 | Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. |
| Q55040154 | Systematic Review and the External Validity of Randomized Controlled Trials in Lupus Nephritis. |
| Q49486030 | Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis |
| Q79878050 | Systemic Lupus Erythematosus Vasculitis: A Current Therapeutic Overview |
| Q59137616 | Systemic Lupus Erythematosus: An Overview of the Disease Pathology and Its Management |
| Q55933861 | Systemic lupus erythematosus |
| Q89919135 | Systemic lupus erythematosus |
| Q40440734 | Systemic lupus erythematosus and infections: a retrospective study in Saudis |
| Q37021770 | Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider |
| Q50848358 | Systemic lupus erythematosus. |
| Q51803434 | Systemic lupus erythematosus. |
| Q46686656 | Systemic lupus erythematosus: clinical manifestations, treatment and economics |
| Q36792304 | Systemic lupus erythematosus: current state of diagnosis and treatment |
| Q34498515 | Systemic lupus erythematosus: review of synthetic drugs |
| Q36951021 | Systemic lupus erythematosus: the face of Asia |
| Q26775707 | The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis |
| Q90167554 | The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis |
| Q44761101 | The NIH pulse cyclophosphamide regime: the end of an era? |
| Q84974441 | The Persistent Challenge of Lupus Nephritis |
| Q57226203 | The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis |
| Q37082037 | The frequency and outcome of lupus nephritis: results from an international inception cohort study |
| Q47606458 | The multifactorial origin of posterior reversible encephalopathy syndrome in cyclophosphamide-treated lupus patients |
| Q35180377 | The outcome of proliferative lupus nephritis with pulse cyclophosphamide therapy |
| Q38829637 | The safety of pharmacological treatment options for lupus nephritis |
| Q81415101 | The treatment of lupus nephritis |
| Q38062341 | The treatment of systemic lupus proliferative nephritis |
| Q43281578 | The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis |
| Q37627356 | The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness |
| Q56380780 | The utility of trough mycophenolic acid levels for the management of lupus nephritis |
| Q36088035 | Theory, targets and therapy in systemic lupus erythematosus |
| Q36084894 | Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients |
| Q36790803 | Thirty years of cyclophosphamide: assessing the evidence |
| Q38686467 | Towards new avenues in the management of lupus glomerulonephritis |
| Q46054284 | Towards treating lupus nephritis without oral steroids: a dream-come-true? |
| Q24202572 | Treatment for lupus nephritis |
| Q24247408 | Treatment for lupus nephritis |
| Q36118534 | Treatment for lupus nephritis: a revisit |
| Q42728756 | Treatment of lupus nephritis |
| Q84127283 | Treatment of lupus nephritis |
| Q35927877 | Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study |
| Q38223302 | Treatment of lupus nephritis: practical issues in Asian countries. |
| Q80089184 | Treatment of proliferative lupus nephritis: a changing landscape |
| Q37822658 | Treatment of proliferative lupus nephritis: a slowly changing landscape |
| Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
| Q35201234 | Treatment of severe proliferative lupus nephritis: the current state |
| Q37288728 | Treatment options for proliferative lupus nephritis: an update of clinical trial evidence |
| Q35019423 | Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. |
| Q51431847 | Triple threat in pregnancy. |
| Q34367705 | Unexpected recovery from longterm renal failure in severe diffuse proliferative lupus nephritis |
| Q36088877 | Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine |
| Q38864797 | Update on Biologic Therapies for Systemic Lupus Erythematosus |
| Q39002132 | Update on Lupus Nephritis |
| Q26777402 | Update on mesenchymal stem cell-based therapy in lupus and scleroderma |
| Q36575376 | Update on the treatment of lupus nephritis |
| Q40311555 | Update on the treatment of systemic lupus erythematosus |
| Q51349898 | Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis. |
| Q46374758 | Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus |
| Q34538062 | Variability of the impact of adverse events on physicians' decision making |
| Q64078464 | Vitamin D Receptor Gene Polymorphism: An Important Predictor of Arthritis Development |
| Q38920435 | Why targeted therapies are necessary for systemic lupus erythematosus |
| Q84600171 | [Immunosuppresive treatment in patients with lupus glomerulonephritis. Review of adverse events] |
| Q84600784 | [Infections in the immunocompromised host. What is the role of the medications?] |
| Q85589119 | [Lupusnephritis] |
| Q81499380 | [Renal manifestations of rheumatic diseases] |
| Q81567306 | [Reversible posterior leucoencephalopathy in systemic lupus] |
| Q82663605 | [Systemic lupus erythematosus--activity and outcome] |
| Q80984232 | [Therapeutical perspectives in systemic lupus erythematosus] |
Search more.